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Myeloperoxidase Serum Levels Predict Risk in Patients
With Acute Coronary Syndromes
Stephan Baldus, MD*; Christopher Heeschen, MD*; Thomas Meinertz, MD; Andreas M. Zeiher, MD;
Jason P. Eiserich, PhD; Thomas Münzel, MD; Maarten L. Simoons, MD; Christian W. Hamm, MD; on
behalf of the CAPTURE Investigators
Background—Polymorphonuclear neutrophils (PMNs) have gained attention as critical mediators of acute coronary
syndromes (ACS). Myeloperoxidase (MPO), a hemoprotein abundantly expressed by PMNs and secreted during
activation, possesses potent proinflammatory properties and may contribute directly to tissue injury. However, whether
MPO also provides prognostic information in patients with ACS remains unknown.
Methods and Results—MPO serum levels were assessed in 1090 patients with ACS. We recorded death and myocardial
infarctions during 6 months of follow-up. MPO levels did not correlate with troponin T, soluble CD40 ligand, or
C-reactive protein levels or with ST-segment changes. However, patients with elevated MPO levels (350 g/L;
31.3%) experienced a markedly increased cardiac risk (adjusted hazard ratio [HR] 2.25 [1.32 to 3.82]; P0.003). In
particular, MPO serum levels identified patients at risk who had troponin T levels below 0.01 g/L (adjusted HR 7.48
[95% CI 1.98 to 28.29]; P0.001). In a multivariate model that included other biochemical markers, troponin T (HR
1.99; P0.023), C-reactive protein (1.25; P0.044), vascular endothelial growth factor (HR 1.87; P0.041), soluble
CD40 ligand (HR 2.78; P0.001), and MPO (HR 2.11; P0.008) were all independent predictors of the patient’s
6-month outcome.
Conclusions—In patients with ACS, MPO serum levels powerfully predict an increased risk for subsequent cardiovascular
events and extend the prognostic information gained from traditional biochemical markers. Given its proinflammatory
properties, MPO may serve as both a marker and mediator of vascular inflammation and further points toward the
significance of PMN activation in the pathophysiology of ACS. (Circulation. 2003;108:1440-1445.)
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Patients with acute coronary syndromes (ACS) are char-acterized by increased platelet activation and aggregation
within the coronary circulation.1 Thrombus formation at a
ruptured or eroded plaque and distal embolization of platelet
aggregates eventually lead to myocyte necrosis.2 In particu-
lar, the occurrence of minor myocardial injury as observed in
ACS is reliably assessed by measuring the release of tro-
ponins, which have emerged as powerful tools for risk
assessment and therapeutic management of patients with
ACS.3,4
There is growing evidence that myocardial cell injury not
only is related to platelet activation but also is preceded by
recruitment and activation of polymorphonuclear neutrophils
(PMNs).5,6 PMNs, despite their apparent insignificance in
coronary atherogenesis, have been shown to increasingly
undergo degranulation within the coronary circulation in
ACS.6 One of the principal mediators secreted on PMN
activation is myeloperoxidase (MPO), a hemoprotein tradi-
tionally viewed as a microbicidal enzyme.7 However, there is
accumulating evidence that MPO also displays potent
proatherogenic properties. For example, MPO can oxidize
LDL cholesterol, thereby propagating uptake by macrophages
and perpetuating foam cell formation.8 Furthermore, MPO
has been shown to activate metalloproteinases and promote
destabilization and rupture of the atherosclerotic plaque
surface.9 Also, MPO catalytically consumes endothelium-
derived nitric oxide, thereby reducing nitric oxide bioavail-
ability and impairing its vasodilatory and anti-inflammatory
functions.10,11
PMNs have been demonstrated to release MPO into the
coronary circulation, yielding elevated MPO plasma levels in
patients with unstable angina and acute myocardial infarc-
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tion.6,12 A case-control study revealed that MPO levels in PMN
and whole blood were independently associated with the prev-
alence of stable coronary artery disease.13 Appreciating that
PMN activation is an early event in ACS, we hypothesized that
MPO levels may identify patients at increased risk for cardio-
vascular events independent of existing myocardial necrosis. We
therefore investigated the prognostic information of MPO serum
levels in patients with ACS using the database of patients with
ACS enrolled in the c7E3 Anti-Platelet Therapy in Unstable
Refractory angina (CAPTURE) trial.14
Methods
Patients
The CAPTURE trial enrolled 1265 patients with ACS (61% males,
aged 6110 years). All CAPTURE patients had recurrent chest pain
at rest associated with ECG changes during treatment with intrave-
nous heparin and nitroglycerin. All patients underwent coronary
angiography before randomization that indicated significant coro-
nary artery disease with a culprit lesion 70% suitable for angio-
plasty. Heparin was administered from before randomization until at
least 1 hour after coronary angioplasty. For all patients, coronary
interventions were scheduled between 18 and 24 hours after begin-
ning study treatment. The patients were randomly assigned to
abciximab or placebo. Primary end points of the study were mortality
and nonfatal myocardial infarction during the 30 days of the
follow-up period.14 Serum samples were collected 8.74.9 hours
after the last episode of chest pain.
Biochemical Analysis
Serum samples were centrally stored at 80°C. Determination of
cardiac markers was performed blinded to patients’ histories and the
allocated treatment at the research laboratory of the University of
Frankfurt. MPO serum levels were measured by ELISA according to
procedures recommended by the manufacturer (Calbiochem). This
assay provides a detection limit of 1.5 g/L. Using internal controls,
total imprecision over the 8-week period was 8.4%. No trend of the
test results toward higher or lower levels was observed during the
8-week study period. Vascular endothelial growth factor and soluble
CD40 ligand (sCD40L) were measured by ELISA (both R&D
Systems). The diagnostic threshold value was 300 g/L for vascular
endothelial growth factor15 and 5.0 g/L for sCD40L.16 Cardiac
troponin T (TnT) was determined with a 1-step enzyme immunoas-
say based on electrochemiluminescence technology (Elecsys 2010,
Roche Diagnostics). The cutoff level for TnT was set at 0.01 g/L.17
High-sensitivity C-reactive protein was measured with the Behring
BN II Nephelometer (Dade Behring Inc). A diagnostic threshold
value of 10 mg/L was used.18,19
Statistical Methods
After blind assessment of the biochemical markers, test results were
merged with the database. To distinguish between patients with
different degrees of cardiac risk, an exploratory data analysis was
chosen. The Cox proportional-hazards regression model was used to
estimate the relative risk for cardiovascular events, and patients were
categorized according to tertiles of MPO concentration.20 Post hoc
analysis of tertiles was performed with the Cox proportional-hazards
regression model with MPO tertiles as a categorical variable; the first
tertile served as the reference group. Receiver operating character-
istics curve analysis over the dynamic range of the MPO assay was
used to identify the threshold level for MPO that provided the highest
predictive value to stratify patients with ACS according to risk. The
effect of baseline characteristics (with P0.10 necessary to enter a
variable into the model) and other biochemical markers on any
observed associations between MPO levels and cardiovascular
events was analyzed with stepwise Cox proportional-hazards mod-
els. All results for continuous variables are expressed as meanSD.
Comparisons between groups were analyzed by t test (2-tailed).
Comparison of categorical variables was generated by the Pearson 2
test. Probability values 0.05 were considered statistically signifi-
cant. All analyses were performed with SPSS 11.0 (SPSS Inc).
Results
Baseline samples were available for 1090 patients enrolled in
the CAPTURE trial (86.2%). The baseline characteristics for
this substudy population were not different from the total
study population with respect to age, gender, cardiovascular
risk profile, and concomitant treatment before and after
randomization. The reduction of cardiac events in the abcix-
imab group of the substudy population was comparable to the
entire CAPTURE study population before PTCA (2.2%
placebo versus 0.9% abciximab; P0.07), after PTCA (7.9%
versus 3.5%; P0.001), and at 30 days (9.0% versus 4.2%;
P0.001).14
MPO Serum Levels and Cardiac Risk
MPO was detectable in baseline serum samples of all study
patients, with a median of 287 g/L (range 1.5 to 1112 g/L).
Because other markers, such as TnT and sCD40L, have been
shown to interact with the treatment effect of the glycoprotein
IIb/IIIa receptor antagonist abciximab, the exploratory anal-
ysis was restricted to the placebo group (n547). Patients
were stratified into tertiles according to their measured MPO
serum levels: MPO-1, 222 g/L (n178); MPO-2, 222 to
350 g/L (n187); and MPO-3, above 350 g/L (n182),
respectively. For the initial 24-hour period, the combined end
points of mortality and nonfatal myocardial infarction re-
vealed a trend between MPO tertiles (P0.17; Figure 1). For
the later follow-up time points (72 hours, 30 days, and 6
months), event rates showed significant differences among
MPO tertiles (Figure 1). Post hoc analysis of tertiles with the
Cox proportional-hazards regression model revealed that only
the third MPO tertile significantly differed from the first
MPO tertile, which served as a reference (72 hours, P0.004;
30 days, P0.008; and 6 months, P0.012).
Figure 1. Association between MPO serum levels and cardiac
event rate according to MPO tertile in placebo group (n547).
Range of MPO was as follows: 222 g/L (1st tertile), 223 to
350 g/L (2nd tertile), and 350 g/L (3rd tertile). Differences in
event rates between tertiles were significant at 72 hours
(P0.001), 30 days (P0.001), and 6 months (P0.001) of
follow-up. MI indicates myocardial infarction.
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When MPO serum levels were linked to traditional risk
markers, neither TnT (r0.04), vascular endothelial growth
factor (r0.03), C-reactive protein serum levels (r0.02),
nor sCD40L, a marker of platelet activation previously found
to be predictive of adverse outcome in the CAPTURE
population16 (r0.06), correlated. Moreover, MPO serum
levels did not differ between patients with TnT serum levels
above and below 0.01 g/L, whereas C-reactive protein
serum levels were significantly higher in patients with TnT
levels 0.01 g/L (Figure 2).
Risk Stratification According to Serum
MPO Status
On the basis of the above results, we categorized the study
population using a threshold level of 350 g/L MPO. Of 547
placebo patients, 171 (31.3%) had MPO serum levels 350
g/L, and 376 patients had levels 350 g/L. As illustrated
in Table 1, there were few significant differences in baseline
characteristics between the 2 groups. Patients with elevated
MPO serum levels were more frequently diabetics, and more
of them had a history of coronary events. For patients with
high MPO serum levels, the combined end point of death and
nonfatal myocardial infarction was significantly different
compared with patients with low MPO serum levels (Table
2). After 72 hours, 14.0% of patients with high MPO serum
levels suffered death and nonfatal myocardial infarction
compared with 5.1% for patients with low MPO serum levels
(P0.001; Figure 3A). During the subsequent 6 months of
follow-up, event rate curves for patients with high and low
MPO serum levels, respectively, did not continue to diverge
(Figure 3B). Accordingly, the significant difference between
patients with high and low MPO serum levels was entirely
related to an increased event rate during the initial 72 hours
after onset of symptoms. The crude event rates were 14.6%
versus 6.4% (P0.003) at 30 days and 18.1% versus 8.8%
(P0.002) at 6 months. This difference was mainly driven by
an increased rate of nonfatal myocardial infarctions. The
single end point mortality at 6-month follow-up did not differ
between groups (2.1% versus 1.8%; P1.00). Consistently,
urgent revascularization procedures, including percutaneous
coronary intervention and CABG, were significantly more
frequent in patients with high MPO serum levels (13.7%
versus 8.1%; P0.014). Nonurgent revascularization proce-
dures during 6 months of follow-up were similar between
patients with high and low MPO serum levels (25.8% versus
26.4%; P0.95).
Multivariate Risk Stratification
In a multivariate analysis that included baseline characteris-
tics and biochemical markers (TnT, vascular endothelial
Figure 2. MPO and C-reactive protein (CRP) serum levels,
respectively, according to baseline TnT status (n547).
TABLE 1. Baseline Characteristics According to MPO Status
for the Placebo Group of the CAPTURE Trial (n547)
MPO Low
(n376)
MPO High
(n171) P
Male 71.4 69.2 0.34
Age, y 61.410.5 62.510.4 0.32
Troponin T 0.01 g/L 62.1 61.2 0.84
C-reactive protein 10 mg/L 45.9 42.7 0.52
sCD40L 5.0 g/L 35.5 43.2 0.11
White blood cell count, 109/L 8.93.1 9.22.7 0.71
ST-segment depression 48.5 48.5 1.00
T-wave inversion 54.8 44.8 0.038
History of angina 7 days 55.3 57.4 0.64
History of infarction 30 days 10.5 16.6 0.022
History of infarction 30 days 20.3 20.4 0.97
PTCA 13.6 20.7 0.024
CABG 2.2 4.9 0.16
Risk factors
Diabetes 8.2 12.5 0.024
Hypertension 35.4 36.9 0.59
Current smokers 42.5 40.0 0.63
Medication at baseline
Aspirin 97.9 98.1 1.00
Intravenous heparin 99.0 98.9 0.98
Intravenous nitrates 99.4 99.3 1.00
-Blockers 63.5 62.9 0.91
Values are percentages unless otherwise indicated.
TABLE 2. Multivariate Cox Proportional-Hazards Regression
Model for Death and Nonfatal Myocardial Infarction During 6
Months of Follow-Up Derived From the Placebo Group of the
CAPTURE Trial
Variable
Adjusted
Hazard
Ratio 95% CI P
Gender 0.98 0.67 to 1.52 0.87
Age 65 y 1.19 0.69 to 1.52 0.57
Diabetes mellitus 1.16 0.59 to 2.64 0.65
Hypercholesterolemia 1.05 0.65 to 1.32 0.78
Current smoker 0.98 0.59 to 1.34 0.65
Hypertension 1.05 0.89 to 1.29 0.99
History of coronary revascularization 0.92 0.64 to 1.25 0.82
ST-segment depression 1.02 0.65 to 1.51 1.00
MPO 350 g/L 2.25 1.32 to 3.82 0.003
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growth factor, C-reactive protein, sCD40L, and white blood
cell count), MPO remained an independent and powerful
predictor of increased cardiac risk both at 30 days of
follow-up (adjusted hazard ratio 1.8 [95% CI 1.1 to 3.3];
P0.013) and at 6 months of follow-up (adjusted hazard ratio
2.1 [95% CI 1.7 to 5.2]; P0.006; Table 3). Division of the
patients into 6 groups based on their MPO and TnT levels
revealed that MPO identified a subgroup of patients with low
TnT serum levels who had significantly increased cardiac
risk: patients with TnT serum levels 0.01 g/L but MPO
serum levels above 350 g/L were at significantly higher risk
than patients who had low levels for both TnT and MPO (15.9%
versus 2.0%; P0.001; Figure 4A). Furthermore, the predictive
value of MPO was independent of systemic inflammation as
evidenced by C-reactive protein. High MPO serum levels
indicated increased cardiac risk both in patients with medium
C-reactive protein serum levels (20.0% versus 5.9%; P0.001)
and in those with low C-reactive protein serum levels (17.8%
versus 0%; P0.001; Fig. 4b). Also, MPO predicted adverse
outcome independent of sCD40L; in patients with low TnT
levels (0.01 g/L) and low sCD40L levels (5 g/L), high
MPO levels remained predictive for increased cardiac risk (9.1%
versus 2.3%; P0.028; Figure 5).
Effect of Abciximab Related to MPO
Serum Levels
Cox proportional-hazards regression model indicated that the
effect of treatment with abciximab tended to be higher in
patients with high MPO serum levels (P0.027). Patients
with elevated MPO serum levels who received abciximab
were at significantly lower risk at 72 hours (adjusted hazard
Figure 3. Kaplan-Meier event rate curves showing cumulative
incidence of death or nonfatal myocardial infarction at 72-hour
(A) and 6-month (B) follow-up according to baseline MPO serum
level (diagnostic threshold 350 g/L; n547); arrow indicates
percutaneous coronary intervention (PCI). Hazard ratios were
adjusted for differences in baseline characteristics. MI indicates
myocardial infarction.
TABLE 3. Multivariate Cox Proportional-Hazards Regression
Model of Multiple Biomarkers for Prediction of Death and
Nonfatal Myocardial Infarction During 6 Months of Follow-Up
Variable
Adjusted
Hazard
Ratio 95% CI P
Troponin T 0.01 g/L 1.99 1.16 to 3.64 0.023
C-reactive protein tertiles 1.25 1.02 to 1.68 0.044
Vascular endothelial growth factor
300 g/L
1.87 1.03 to 3.51 0.041
sCD40L 5 g/L 2.78 1.57 to 4.91 0.001
MPO 350 g/L 2.11 1.21 to 3.67 0.008
Figure 4. Predictive value of MPO for incidence of death and
nonfatal myocardial infarction according to TnT serum levels (A)
and C-reactive protein (CRP) serum levels (B). Diagnostic
threshold levels were 222 and 350 g/L for MPO, 0.01 and 0.1
g/L for TnT, and 5 and 15 mg/L for C-reactive protein (n547).
MI indicates myocardial infarction.
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ratio 0.22 [95% CI 0.09 to 0.54]; P0.001) and 30 days of
follow-up (adjusted hazard ratio 0.24 [95% CI 0.10 to 0.58];
P0.001). This significant difference was maintained at 6
months of follow-up (0.39 [95% CI 0.20 to 0.76]; P0.006).
However, in a multivariate model that included TnT,
sCD40L, and MPO, sCD40L (P0.001) remained the only
independent predictor of the effect of abciximab.
Discussion
The results of the present study establish MPO serum levels
as a powerful independent prognostic determinant of clinical
outcome in patients with ACS. Most notably, in patients with
TnT serum levels below 0.01 g/L, elevated MPO serum
levels identify a subgroup of patients who have significantly
increased cardiac risk (adjusted hazard ratio 7.48 [95% CI
1.98 to 28.29]; P0.001). In conjunction with TnT, MPO
identified 95% of all adverse events in CAPTURE.
Risk stratification in patients with ACS remains a major
objective for the selection of optimal medical and interven-
tional treatment regimens. Troponins are the most established
prognostic markers in that they reliably predict adverse
cardiac events and identify those patients who derive major
benefit from intensified antiplatelet therapy with glycoprotein
IIb/IIIa receptor antagonists.4 Because troponins reflect myo-
cardial injury and necrosis, efforts remain to identify patients
at risk during an earlier stage of the disease.
Pathophysiologically, platelet activation and thrombus for-
mation are considered a central contributor to the develop-
ment of ischemia and myocardial injury, as demonstrated by
the profound benefit of antiaggregatory regimens in ACS.
sCD40L, a protein released by platelets on activation, has
been demonstrated to predict adverse outcome in ACS and
proved to identify those patients who derive benefit from
glycoprotein IIb/IIIa receptor antagonists.16 In contrast to
platelet activation, recruitment and degranulation of PMNs
only recently gained attention in ACS and has been charac-
terized as a localized event within the coronary circula-
tion.6,21–23 One of the principal enzymes secreted by activated
neutrophils is MPO, a hemoprotein that accounts for 4% of
total cellular protein. PMNs are the foremost cellular source
of intravascular MPO and contribute to 95% of total circu-
lating MPO content.13
MPO serum levels in patients enrolled in the CAPTURE
trial were up to 20-fold higher than those reported previously
for healthy subjects.24 Given the site-specific degranulation of
PMNs in the coronary circulation6 and the fact that blood was
obtained from a peripheral vein, the systemic MPO levels
obtained in the present study presumably reflect even higher
local MPO concentrations in the coronary circulation. As
reported earlier, MPO binds to glycosaminoglycans on endo-
thelial cell surfaces and is released by administration of
heparin derivatives.25 Because all CAPTURE patients re-
ceived heparin, circulating MPO levels in the present study
may also represent MPO that was bound to the coronary
endothelium. Here, MPO may contribute to a local proinflam-
matory milieu, eg, by catabolism of endothelium-derived
nitric oxide.11,26
Interestingly, MPO levels were equally distributed among
patients with low and high TnT serum levels (Figure 2),
which indicates that elevated MPO serum levels are not
temporally related to myocardial injury. More importantly,
MPO identified patients at risk for cardiovascular events who
had low baseline TnT serum levels. These data suggest that
MPO release actually precedes myocardial injury and that
MPO elevation identifies patients with unstable atheroscle-
rotic plaque formation even before complete microvascular
obstruction. In addition, ECG evidence of myocardial ische-
mia did not correlate with MPO levels (Table 2), which
further reinforces the notion that MPO release is a prerequi-
site rather than a consequence of myocardial injury.
Surprisingly, MPO levels did not correlate with C-reactive
protein, a systemic marker of inflammation and the most
well-characterized measure for identifying patients with sta-
ble coronary artery disease who are at risk for future
cardiovascular events.27 Mean C-reactive protein levels in the
CAPTURE study were 18.326.9 mg/L. Because C-reactive
protein correlated with TnT levels (Figure 2), elevated
C-reactive protein serum levels most likely reflect both a
robust vascular inflammatory response and myocardial inju-
ry.5 However, in patients with low CRP levels, MPO identi-
fied those with increased risk for cardiac events (Figure 4B),
which suggests that recruitment and degranulation of PMNs
is a primary event and is followed by release of other
systemic mediators and acute-phase proteins such as
C-reactive protein.
Another important finding of the present study is that
MPO, sCD40L, and TnT all emerged as independent predic-
tors of adverse outcome. The combination of MPO and
sCD40L was especially revealing in patients with low TnT
levels. With the cutoff for TnT being lowered to 0.01 g/L,
neither TnT nor MPO but only sCD40L independently
identified those patients who derived benefit from abciximab,
which may underscore the specificity of a treatment regimen
directed against a receptor expressed on activated platelets.
This may further imply that neutrophil activation represents
an adjunct pathophysiological event in ACS that is distinctly
different from platelet activation. Eventually, platelet and
neutrophil activation may contribute to the same “down-
Figure 5. MPO identifies patients with adverse events (death,
nonfatal myocardial infarction) independent of TnT (diagnostic
threshold level for TnT was 0.01 g/L) and sCD40L (diagnostic
threshold level for sCD40L was 5 g/L) status (n547). MI indi-
cates myocardial infarction.
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stream” event, that is, myocardial injury as reflected by the
release of troponins.
In conclusion, the present study revealed that MPO is a
powerful predictor of adverse outcome in patients with ACS.
Particularly in individuals with low TnT levels, MPO iden-
tified patients at increased risk for future cardiovascular
events. This suggests that MPO unmasks states of acute
inflammation in the coronary circulation indicative of in-
creased neutrophil activation, which ultimately precedes
myocardial injury. Thus, MPO levels not only stratify risk in
patients with ACS but also shed light on the underlying
pathophysiology, which is activation and degranulation of
PMN being a critical component of acute coronary inflam-
mation. The data obtained from the present study extend the
understanding of ACS in that they reveal that neutrophil
activation is a thus far underrecognized event during coronary
inflammation. Given the emerging body of evidence for
proinflammatory properties of MPO, the enzyme by itself
may not only be a marker of neutrophil activation but also
may be a direct contributor to the inflammatory milieu during
ACS. Although future prospective studies are warranted to
confirm these results, the present findings support the ratio-
nale to further evaluate MPO for risk stratification in patients
with ACS and encourage the development of pharmacologi-
cal strategies to modulate the catalytic activity of this
enzyme.
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